Hydroxyprogesterone caproate has been studied in humans at doses as high as 5,000 mg per week by intramuscular injection, with safety and without glucocorticoid effects observed. The medication does interact with the glucocorticoid receptor however; it has about 4% of the affinity of dexamethasone for the rabbit glucocorticoid receptor. But it acts as a partial agonist of the receptor and has no greater efficacy than progesterone in activating the receptor and eliciting associated gene expression in vitro.
Hydroxyprogesterone caproate has been investigated in humans at doses up to 5,000 mg per week via intramuscular injection, demonstrating safety without glucocorticoid effects. The medication interacts with the glucocorticoid receptor; it has about 4% of dexamethasone's affinity for the rabbit receptor. It acts as a partial agonist and does not show greater efficacy than progesterone in activating the receptor and inducing gene expression in vitro.